Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Zhonghua Nan Ke Xue ; 29(9): 846-850, 2023 Sep.
Artigo em Chinês | MEDLINE | ID: mdl-38639600

RESUMO

OBJECTIVE: To study the clinical therapeutic effect as well as drug effectiveness and safety of Shizi Sanhua decoction combined with Nuoyu in the treatment of oligozoospermia in men. METHODS: 102 patients with oligozoospermia diagnosed at Longhua Hospital of Shanghai University of Traditional Chinese Medicine from February 2022 to March 2023 were selected and randomly divided into 3 groups. The treatment group was treated with Shizi Sanhua Decoction + Nuoyu; the traditional Chinese medicine group was treated with Shizi Sanhua Decoction; and the Nuoyu nutrient group was treated with Nuoyu nutrient. A review assessment and record were made after one course of treatment (3 months). RESULTS: A total of 102 patients completed the trial due to the treatment process. There were 34 cases in each of the traditional Chinese medicine group, the Nuoyu nutrient group, and the treatment group. Clinical efficacy: total effective rate of 52.94% in the traditional Chinese medicine group; 58.82% in the Nuoyu nutrient group; 82.35% in the treatment group. The clinical efficacy of the treatment group was better than that of the traditional Chinese medicine group and the Nuoyu nutrient group (P<0.05), which was statistically significant. Semen routine: the treatment group was better than the traditional Chinese medicine group and Nuoyu nutrient group in improving the total number of sperm and sperm concentration. CONCLUSION: The semen concentration and forward sperm count of patients with oligozoospermia treated with Shizi Sanhua Decoction combined with Nuoyu improved more significantly, and the clinical efficacy was remarkable. And the clinical efficacy is not affected by age and disease duration. It can be popularized and applied as a treatment for oligozoospermia.


Assuntos
Medicamentos de Ervas Chinesas , Oligospermia , Humanos , Masculino , Medicamentos de Ervas Chinesas/uso terapêutico , Oligospermia/tratamento farmacológico , Oligospermia/induzido quimicamente , Sêmen , China , Medicina Tradicional Chinesa
2.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 21(3): 770-4, 2013 Jun.
Artigo em Chinês | MEDLINE | ID: mdl-23815938

RESUMO

The study was aimed to investigate the mechanism of mannan-binding lectin (MBL) on bacterial lipopolysaccharide (LPS)-induced human peripheral blood monocyte-derived dendritic cell (DC) maturation. The monocytes were prepared from the peripheral blood of healthy adult volunteers. The immature dendritic cells (imDC) were induced by 5-day-culture in medium supplemented with rhGM-CSF and rhIL-4. FACS was used to investigate the interaction of MBL with imDC and the impact of MBL on LPS binding to imDC. ELISA and Western blot was used to analyze the interaction of MBL with soluble TLR4 ectodomain protein (sTLR4); Western blot was used to detect LPS-induced NF-κB translocation in imDC. The results showed that MBL could directly bind to imDC in the presence of calcium. sTLR4 protein or LPS could competitively inhibit the binding of MBL to imDC. ELISA and Western blot showed that MBL could evidently bind to sTLR4 protein in a concentration-dependent manner. FACS showed that MBL could competitively inhibit the binding of LPS to imDC by binding to imDC directly. Western blot showed that MBL decreased LPS-induced NF-κB translocation in imDC. It is concluded that MBL may competitively inhibit the binding of LPS to imDC by binding to TLR4 expressed on imDC, resulted in inhibition of LPS-induced DC maturation, suggesting that MBL can regulate DC maturation through ligand-binding. This study provides the good foundation to clarify the mechanism of MBL inhibiting the LPS-induced DC maturation.


Assuntos
Células Dendríticas/citologia , Células Dendríticas/metabolismo , Lectina de Ligação a Manose/farmacologia , Diferenciação Celular , Células Cultivadas , Células Dendríticas/efeitos dos fármacos , Humanos , Ligantes , Lipopolissacarídeos/efeitos adversos , Monócitos/citologia , Monócitos/metabolismo , Receptor 4 Toll-Like/metabolismo
3.
Zhong Yao Cai ; 30(5): 573-5, 2007 May.
Artigo em Chinês | MEDLINE | ID: mdl-17727066

RESUMO

OBJECTIVE: To study the effect of lipid-regulating function for extracts and their prescriptions from Semen Cassiae and Crataegus pinnatifida Bge. var. major N. E. Br. on serum lipid of hyperlipidema mice. METHODS: 1 week after being administered with extract of Semen Cassiae, extract of Crataegus pinatifida Bge. var. major N. E. Br. and different proportion mixture of them (180 mg/ kg), mice were treated with ip 75% fresh yelkfluid. The contents of TC, TG, HDL-C, LDL-C, apo AI and apo B were observed after 24 h. RESULTS: The levels of TC, TG, LDL-C and apoB in therapeutic group were lower than those in hyperlipidemic model group (P < 0.05, P < 0.01), especially in different proportion mixture groups. CONCLUSION: Lipid-regulating active part of Semen Cassiae and Crataegus pinatifida Bge. var. major N. E. Br. might inhibit hyperlipidemic formation, and mixture groups were more effective than those of its single extract.


Assuntos
Medicamentos de Ervas Chinesas/farmacologia , Hiperlipidemias/prevenção & controle , Hipolipemiantes/farmacologia , Lipídeos/sangue , Plantas Medicinais/química , Animais , Cassia/química , Colesterol/sangue , LDL-Colesterol/sangue , Crataegus/química , Medicamentos de Ervas Chinesas/administração & dosagem , Medicamentos de Ervas Chinesas/uso terapêutico , Frutas/química , Hiperlipidemias/sangue , Hiperlipidemias/patologia , Hipolipemiantes/administração & dosagem , Hipolipemiantes/uso terapêutico , Masculino , Camundongos , Fitoterapia , Sementes/química , Triglicerídeos/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA